1. Home
  2. PBLS vs CNS Comparison

PBLS vs CNS Comparison

Compare PBLS & CNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PBLS

Parabilis Medicines Inc. Common Stock

N/A

Current Price

$30.20

Market Cap

3.4B

Sector

Health Care

ML Signal

N/A

Logo Cohen & Steers Inc

CNS

Cohen & Steers Inc

HOLD

Current Price

$79.27

Market Cap

3.7B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
PBLS
CNS
Founded
N/A
1986
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.7B
IPO Year
2026
2004

Fundamental Metrics

Financial Performance
Metric
PBLS
CNS
Price
$30.20
$79.27
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
$71.50
AVG Volume (30 Days)
582.4K
310.8K
Earning Date
N/A
04-16-2026
Dividend Yield
N/A
3.96%
EPS Growth
N/A
N/A
EPS
N/A
0.82
Revenue
N/A
$427,536,000.00
Revenue This Year
N/A
$4.71
Revenue Next Year
N/A
$4.37
P/E Ratio
N/A
$96.89
Revenue Growth
N/A
4.07
52 Week Low
$25.56
$58.39
52 Week High
$30.19
$80.21

Technical Indicators

Market Signals
Indicator
PBLS
CNS
Relative Strength Index (RSI) 63.50 63.50
Support Level $26.68 $59.88
Resistance Level $30.19 N/A
Average True Range (ATR) 2.38 2.03
MACD 0.24 0.16
Stochastic Oscillator 75.32 82.98

Price Performance

Historical Comparison
PBLS
CNS

About PBLS Parabilis Medicines Inc. Common Stock

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

About CNS Cohen & Steers Inc

Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for around two-thirds of its $98.4 billion in managed assets at the end of February. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 39% (25%) of its managed assets (base management fees) from institutional clients, 48% (55%) from open-end funds, and 13% (20%) from closed-end funds.

Share on Social Networks: